Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 32.1% from a year ago
Total equity stood at $14.22M at the end of Q1 FY2026, down 32.1% from a year earlier and down 22.8% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.
Context
- Total equity amounted to 56.0% of total assets at the end of Q1 FY2026, down 13.5 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -32.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 18.41M USD
- Year-over-year change
- +89.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.41M | +89.6% |
| FY2024 | 2024-12-31 | 9.71M | -20.4% |
| FY2023 | 2023-12-31 | 12.2M | -14.2% |
| FY2022 | 2022-12-31 | 14.22M | +229.2% |
| FY2021 | 2021-12-31 | (11.01M) | — |
Total Equity vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total equity of $14.22M is the lowest of the 11 companies compared; the peer median is $135.42M.
- Its year-over-year change of -32.1% is the 8th highest of 11, against a peer median of +31.0%.
- Total equity amounts to 56.0% of total assets for NVCT, versus a peer median of 85.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $206.52B | +493455.8% | +25.8% | 96.1% | |
| Mar 2026 | $941.54M | -7.0% | +44.0% | 91.6% | |
| Mar 2026 | $415.56M | +89.1% | +20.0% | 95.1% | |
| Jun 2026 | $253.86M | -31.9% | -22.4% | 34.1% | |
| Mar 2026 | $186.47M | +69.1% | +2.7% | 90.9% | |
| Mar 2026 | $84.36M | +779.4% | +92.4% | 88.0% | |
| Mar 2026 | $81.78M | +352.1% | +6.5% | 35.9% | |
| Mar 2026 | $41.62M | -80.6% | -48.3% | 8.8% | |
| Mar 2026 | $34.05M | -43.3% | -7.3% | 83.8% | |
| Mar 2026 | $21.2M | -73.2% | -26.8% | 9.7% | |
| Mar 2026 | $14.22M | -32.1% | +9.0% | 56.0% | |
| Peer median (excluding NVCT) | $135.42M | +31.0% | +4.6% | 85.9% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.